# Camrelizumab Combined With Apatinib Mesylate for Head and Neck Squamous Cell Carcinoma

> **NCT04440917** · PHASE2 · UNKNOWN · sponsor: **Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University** · enrollment: 32 (estimated)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Camrelizumab
- **DRUG:** Apatinib Mesylate

## Key facts

- **NCT ID:** NCT04440917
- **Lead sponsor:** Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06-03
- **Primary completion:** 2022-06
- **Final completion:** 2023-12
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2021-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04440917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04440917, "Camrelizumab Combined With Apatinib Mesylate for Head and Neck Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04440917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*